Total Payments
$17,979
2024 Payments
$3,578
Companies
38
Transactions
810
Medicare Patients
8,704
Medicare Billing
$856,200
Payment Breakdown by Category
Food & Beverage$15,148 (84.3%)
Consulting$2,250 (12.5%)
Education$580.63 (3.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,148 | 795 | 84.3% |
| Consulting Fee | $2,250 | 1 | 12.5% |
| Education | $580.63 | 14 | 3.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. | $2,571 | 18 | $0 (2024) |
| ABBVIE INC. | $2,353 | 131 | $0 (2024) |
| PFIZER INC. | $1,443 | 84 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,295 | 67 | $0 (2024) |
| Lilly USA, LLC | $1,171 | 75 | $0 (2024) |
| Janssen Biotech, Inc. | $1,167 | 57 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $1,107 | 43 | $0 (2024) |
| Incyte Corporation | $926.94 | 46 | $0 (2024) |
| GENZYME CORPORATION | $786.36 | 32 | $0 (2024) |
| LEO Pharma Inc. | $733.59 | 52 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,578 | 189 | ABBVIE INC. ($498.11) |
| 2023 | $5,662 | 172 | Arcutis Biotherapeutics, Inc. ($2,405) |
| 2022 | $2,258 | 119 | ABBVIE INC. ($538.08) |
| 2021 | $1,753 | 95 | AbbVie Inc. ($262.38) |
| 2020 | $1,100 | 55 | AbbVie Inc. ($246.71) |
| 2019 | $1,827 | 99 | PFIZER INC. ($214.26) |
| 2018 | $1,168 | 58 | AbbVie, Inc. ($187.24) |
| 2017 | $632.19 | 23 | DUSA Pharmaceuticals, Inc. ($267.12) |
All Payment Transactions
810 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $11.32 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: DERMATOLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $8.74 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $4.35 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: Inflammation | ||||||
| 12/04/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $10.45 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $28.48 | General |
| Category: Dermatology | ||||||
| 12/03/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | BLU-U (Medical Supply), Odomzo | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: Dermatology | ||||||
| 11/22/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $89.99 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: Dermatology | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: Immunology | ||||||
| 11/14/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: DERMATOLOGY | ||||||
| 11/13/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: Inflammation | ||||||
| 11/13/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $6.45 | General |
| 11/13/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $6.25 | General |
| 11/08/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: DERMATOLOGY | ||||||
| 11/08/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Dermatology | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: Immunology | ||||||
| 11/06/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $6.06 | General |
| Category: Dermatology | ||||||
| 10/31/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $25.74 | General |
| Category: DERMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 2,718 | 12,369 | $626,951 | $258,070 |
| 2022 | 21 | 2,410 | 11,949 | $586,275 | $240,444 |
| 2021 | 20 | 2,000 | 8,712 | $484,115 | $200,287 |
| 2020 | 17 | 1,576 | 7,685 | $436,384 | $157,399 |
Total Patients
8,704
Total Services
40,715
Medicare Billing
$856,200
Procedure Codes
80
All Medicare Procedures & Services
80 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 448 | 759 | $145,273 | $73,879 | 50.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 497 | 725 | $93,561 | $47,228 | 50.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 264 | 361 | $67,425 | $33,558 | 49.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 462 | 722 | $107,831 | $30,931 | 28.7% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 151 | 167 | $29,491 | $12,283 | 41.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 357 | 2,091 | $73,185 | $12,264 | 16.8% |
| J7345 | Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 2023 | 31 | 6,800 | $18,056 | $8,602 | 47.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 58 | 58 | $17,156 | $7,134 | 41.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 69 | 69 | $13,307 | $5,467 | 41.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 100 | 114 | $8,926 | $4,651 | 52.1% |
| 96567 | Application of light to destroy precancer skin growth | Office | 2023 | 33 | 36 | $8,568 | $4,598 | 53.7% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 22 | 26 | $11,960 | $3,917 | 32.8% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 20 | 26 | $8,369 | $3,569 | 42.6% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 18 | 19 | $4,218 | $2,051 | 48.6% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 31 | 41 | $4,221 | $1,544 | 36.6% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 11 | 14 | $3,715 | $1,521 | 41.0% |
| 11300 | Shaving of skin growth of body, arms, or legs, 0.5 cm or less | Office | 2023 | 16 | 18 | $2,297 | $1,318 | 57.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 26 | 28 | $2,667 | $1,264 | 47.4% |
| 17260 | Destruction of cancer skin growth of trunk, arms, or legs, 0.5 cm or less | Office | 2023 | 11 | 12 | $2,088 | $797.14 | 38.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 12 | 12 | $1,601 | $686.73 | 42.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 31 | 53 | $2,345 | $628.80 | 26.8% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 50 | 218 | $691.06 | $181.10 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 364 | 712 | $136,277 | $67,944 | 49.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 397 | 565 | $72,913 | $37,683 | 51.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 237 | 325 | $65,903 | $30,614 | 46.5% |
About Brook Brouha, MD/PHD
Brook Brouha, MD/PHD is a Dermatopathology healthcare provider based in La Jolla, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/12/2008. The National Provider Identifier (NPI) number assigned to this provider is 1114173937.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Brook Brouha, MD/PHD has received a total of $17,979 in payments from pharmaceutical and medical device companies, with $3,578 received in 2024. These payments were reported across 810 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($15,148).
As a Medicare-enrolled provider, Brouha has provided services to 8,704 Medicare beneficiaries, totaling 40,715 services with total Medicare billing of $856,200. Data is available for 4 years (2020–2023), covering 80 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatopathology
- Location La Jolla, CA
- Active Since 08/12/2008
- Last Updated 04/06/2017
- Taxonomy Code 207ND0900X
- Entity Type Individual
- NPI Number 1114173937
Products in Payments
- DUPIXENT (Biological) $1,311
- EUCRISA (Drug) $1,211
- TALTZ (Drug) $1,108
- SKYRIZI (Biological) $972.43
- TREMFYA (Drug) $954.26
- OPZELURA (Drug) $741.96
- RINVOQ (Biological) $738.46
- ILUMYA (Biological) $417.02
- ENSTILAR (Drug) $379.30
- Humira (Biological) $365.94
- Odomzo (Drug) $363.57
- COSENTYX (Biological) $360.56
- Cimzia (Drug) $357.70
- Otezla (Drug) $342.81
- ADBRY (Biological) $299.29
- LIBTAYO (Biological) $289.75
- Winlevi (Drug) $276.19
- COSENTYX (Drug) $268.20
- DUPIXENT (Drug) $235.46
- CIBINQO (Drug) $207.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.